Prostate Adenocarcinoma: Clinical Trials

32 trials for Prostate Adenocarcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 completed, 6 terminated, 4 active not recruiting, 4 recruiting. 32 Phase 1, 9 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 132Completed 16, Terminated 6, Active not recruiting 4, Recruiting 4, Unknown 2
Phase 29Completed 4, Terminated 3, Active not recruiting 1, Unknown 1

Follow Prostate Adenocarcinoma: new trials by email Literature Review of Prostate Adenocarcinoma trials Research Report on Prostate Adenocarcinoma

Trials (filtered) newest first · largest first

All 32 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
Copper 61-PSMA PET/CT - Prostate Adenocarcinoma
Phase 1RecruitingHoag Memorial Hospital Presbyterian82024-10-142024-12-16
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
enzalutamide - Prostate Adenocarcinoma
Phase 1RecruitingAlessa Therapeutics Inc.452024-06-212026-08-11
PSMA PET Response Guided SabR in High Risk Pca
68-Ga PSMA11 - Prostate Adenocarcinoma
Phase 1RecruitingUniversity of Texas Southwestern Medical Center202024-03-072026-04-14
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
Biospecimen Collection, Computed Tomography, External Beam Radiation Therapy - Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Phase 1Active not recruitingEmory University62023-11-292025-12-09
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
BL-B01D1 - Non Small Cell Lung Cancer, Esophageal Cancer
Phase 1RecruitingSystImmune Inc.5402023-08-082026-09-21
A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
Relugolix Pill, Ritonavir, Itraconazole - Prostate Cancer, Prostate Cancer Metastatic
Phase 1TerminatedUniversity of Chicago602023-02-132024-09-19
Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.
Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log - Prostate Cancer, Prostate Adenocarcinoma
Phase 1TerminatedUniversity of Chicago502023-01-242025-10-03
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
bicalutamide, Stereotactic body radiation therapy - Prostate Adenocarcinoma
Phase 1Active not recruitingAlessa Therapeutics Inc.202021-12-072026-02-27
Fluorescent Imaging of Nerves With Illuminare-1 During Surgery
Illuminare-1, Karl Storz D-Light C photodynamic diagnostic (PDD) - Prostate Adenocarcinoma
Phase 1CompletedMemorial Sloan Kettering Cancer Center412021-10-042025-09-16
An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer
Fluorine F 18 rhPSMA-7.3, Magnetic Resonance Imaging, Positron Emission Tomography - Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma
Phase 1CompletedM.D. Anderson Cancer Center292021-08-042024-10-23
Hypo-Combi Trial: Hypofractionated EBRT Plus HDR-BT Boost for Prostate Cancer
External beam radiation therapy, High-dose-rate brachytherapy, Goserelin 10.8 mg - Prostate Adenocarcinoma, Radiation Toxicity
Phase 1 / Phase 2Active not recruitingGerman Oncology Center, Cyprus402021-08-012026-09-17
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
Hypofractionated Radiation Therapy - Prostate Cancer, Prostate Adenocarcinoma
Phase 1Active not recruitingUniversity of Maryland, Baltimore182020-11-192026-11-05
A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer
Bicalutamide implant - Prostate Adenocarcinoma, Lower Urinary Tract Symptoms
Phase 1CompletedAlessa Therapeutics Inc.172020-10-112024-06-24
Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer
Epidiolex Oral Liquid Product - Prostate Cancer Recurrent, Prostate Cancer
Phase 1CompletedZin W Myint212020-08-032025-03-05
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
Gonadotrophin Releasing Hormone, Intensity-Modulated Radiation Therapy, Niraparib - Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
Phase 1 / Phase 2CompletedNRG Oncology222019-10-082026-07-10
A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
Talazoparib, Temozolomide - Prostate Cancer, Prostate Adenocarcinoma
Phase 1 / Phase 2TerminatedMemorial Sloan Kettering Cancer Center162019-07-112026-08-24
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
Lutetium Lu 177-PSMA-617, Pembrolizumab - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Phase 1CompletedUniversity of California, San Francisco432019-05-102025-02-25
Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer
Entinostat, Enzalutamide - Prostate Adenocarcinoma
Phase 1TerminatedGeorge Washington University62019-05-012021-08-02
Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer
Daratumumab, FMS Inhibitor JNJ-40346527, Radical Prostatectomy - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8
Phase 1CompletedM.D. Anderson Cancer Center332017-06-072024-05-03
A Study Evaluating MM-310 in Patients With Solid Tumors
MM-310 - Solid Tumors, Urothelial Carcinoma
Phase 1UnknownMerrimack Pharmaceuticals342017-02-222018-02-27

Showing 20 of 32. Sign in to see all of them.

Narrower conditions

Prostatic Neoplasms (17)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Breast Neoplasms (2)  ·  Endometrial Neoplasms (2)  ·  Melanoma (2)  ·  Ovarian Neoplasms (2)  ·  Small Cell Lung Carcinoma (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Triple Negative Breast Neoplasms (2)  ·  Breast Neoplasms, Male (1)  ·  Carcinoma, Transitional Cell (1)  ·  Colorectal Neoplasms (1)  ·  Esophageal Neoplasms (1)  ·  Glioma (1)  ·  Lower Urinary Tract Symptoms (1)

Broader conditions

Neoplasms by Site (21)  ·  Neoplasms (20)  ·  Genital Diseases (19)  ·  Urogenital Diseases (19)  ·  Urogenital Neoplasms (19)  ·  Genital Diseases, Male (17)  ·  Genital Neoplasms, Male (17)  ·  Male Urogenital Diseases (17)  ·  Prostatic Diseases (17)  ·  Skin Diseases (5)  ·  Skin and Connective Tissue Diseases (5)  ·  Breast Diseases (4)  ·  Bronchial Neoplasms (4)  ·  Carcinoma, Bronchogenic (4)  ·  Lung Diseases (4)

Interventions

Magnetic Resonance Spectroscopy (3)  ·  Goserelin (2)  ·  Radiosurgery (2)  ·  X-Rays (2)  ·  bicalutamide (2)  ·  enzalutamide (2)  ·  pembrolizumab (2)  ·  Abiraterone Acetate (1)  ·  Androgen Antagonists (1)  ·  BCT-100 (1)  ·  Calcitriol (1)  ·  Carboplatin (1)  ·  Chlorotoxin (1)  ·  Congresses as Topic (1)  ·  Gonadotropin-Releasing Hormone (1)

Sponsors

Alessa Therapeutics Inc. (3)  ·  M.D. Anderson Cancer Center (3)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  NRG Oncology (2)  ·  National Cancer Institute (NCI) (2)  ·  University of Chicago (2)  ·  Bio-Cancer Treatment International Limited (1)  ·  Emory University (1)  ·  George Washington University (1)  ·  German Oncology Center, Cyprus (1)  ·  Hoag Memorial Hospital Presbyterian (1)  ·  Institut Cancerologie de l'Ouest (1)  ·  Massachusetts General Hospital (1)  ·  Merrimack Pharmaceuticals (1)  ·  Roswell Park Cancer Institute (1)

Countries

United States (29)  ·  Canada (3)  ·  France (2)  ·  Australia (1)  ·  Cyprus (1)  ·  Italy (1)  ·  Japan (1)  ·  New Zealand (1)  ·  Spain (1)  ·  Switzerland (1)

Top investigators

Alberto Bessudo, MD (1)  ·  Andrew A Loblaw (1)  ·  Christopher Logothetis (1)  ·  Dana Rathkopf (1)  ·  David M Schuster, MD, FACR (1)  ·  Deborah Citrin, MD (1)  ·  Devaki Shilpa S Surasi (1)  ·  Douglas G McNeel, MD PhD (1)  ·  Iosif Strouthos, MD PhD (1)  ·  Jay-Jiguang Zhu, MD (1)  ·  Jeffrey Raizer, M.D. (1)  ·  Jianquig Lin, MD (1)  ·  Jimmy Zhao, MD, PhD (1)  ·  John Fiveash, MD (1)  ·  Karen Autio, MD (1)

Results publications

PMID 20818327, PMID 23553848, PMID 29776373, PMID 29876010, PMID 30700328, PMID 31400383, PMID 31515154, PMID 33885704, PMID 35277461, PMID 37419394, PMID 37619656, PMID 37922930, PMID 38407630, PMID 40601345, PMID 40906325, PMID 41363974, PMID 41378786

NIH funding

P30CA016672 (3), U10CA180868 (2), N01CM00039 (1), N01CM62202 (1), P30CA008748 (1), P30CA016056 (1), P30CA138292 (1), R01CA229354 (1), U01CA062461 (1), U01CA062491 (1), U01CA069856 (1), U10CA021661 (1), ZIABC010850 (1), ZIABC011081 (1), ZIABC011552 (1)